A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
National Institute of Allergy and Infectious Diseases (NIAID)
To determine the frequency of complete, marked, and partial clinical responses in patients
with cryptosporidiosis treated with 6 weeks of NTZ versus 21 days of placebo. To determine
the safety of NTZ in subjects with cryptosporidiosis.
There is no proven therapy for cryptosporidiosis in persons with AIDS. Nitazoxanide appears
to be a good candidate drug for further evaluation because of its effectiveness in
preclinical models, the data from early clinical trials and its safety profile. Cooperation
between clinical researchers and basic scientists in clinical trials of agents for HIV
infection and its complications is a high priority for the ACTG, the NIAID, and the NIH.
Thus, it is important to design a clinical trial of NTZ that includes cooperation with basic
A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea
To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients
with AIDS-related cryptosporidial diarrhea. To determine steady state concentrations of NTZ
following repeated dosing. To assess the safety and efficacy of 4 dose levels of NTZ in these
Cryptosporidial enterocolitis in AIDS patients is frequently chronic and severe, contributing
substantially to morbidity, mortality, and health care costs in this population. NTZ exhibits
antimicrobial activity that may extend to Cryptosporidial infection.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.